These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 35805837)

  • 1. Differences in Immunological Evasion of the Delta (B.1.617.2) and Omicron (B.1.1.529) SARS-CoV-2 Variants: A Retrospective Study on the Veneto Region's Population.
    Cocchio S; Zabeo F; Facchin G; Piva N; Venturato G; Marcon T; Saia M; Tonon M; Mongillo M; Da Re F; Russo F; Baldo V
    Int J Environ Res Public Health; 2022 Jul; 19(13):. PubMed ID: 35805837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.
    Nielsen KF; Moustsen-Helms IR; Schelde AB; Gram MA; Emborg HD; Nielsen J; Hansen CH; Andersen MA; Meaidi M; Wohlfahrt J; Valentiner-Branth P
    PLoS Med; 2022 Nov; 19(11):e1004037. PubMed ID: 36413551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of previous infection with SARS-CoV-2 in protecting against omicron reinfections and severe complications of COVID-19 compared to pre-omicron variants: a systematic review.
    Arabi M; Al-Najjar Y; Sharma O; Kamal I; Javed A; Gohil HS; Paul P; Al-Khalifa AM; Laws S; Zakaria D
    BMC Infect Dis; 2023 Jun; 23(1):432. PubMed ID: 37365490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
    Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR
    JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerland-A multicentre cohort study.
    Babouee Flury B; Güsewell S; Egger T; Leal O; Brucher A; Lemmenmeier E; Meier Kleeb D; Möller JC; Rieder P; Rütti M; Schmid HR; Stocker R; Vuichard-Gysin D; Wiggli B; Besold U; McGeer A; Risch L; Friedl A; Schlegel M; Kuster SP; Kahlert CR; Kohler P;
    PLoS Med; 2022 Nov; 19(11):e1004125. PubMed ID: 36342956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
    Thompson MG; Natarajan K; Irving SA; Rowley EA; Griggs EP; Gaglani M; Klein NP; Grannis SJ; DeSilva MB; Stenehjem E; Reese SE; Dickerson M; Naleway AL; Han J; Konatham D; McEvoy C; Rao S; Dixon BE; Dascomb K; Lewis N; Levy ME; Patel P; Liao IC; Kharbanda AB; Barron MA; Fadel WF; Grisel N; Goddard K; Yang DH; Wondimu MH; Murthy K; Valvi NR; Arndorfer J; Fireman B; Dunne MM; Embi P; Azziz-Baumgartner E; Zerbo O; Bozio CH; Reynolds S; Ferdinands J; Williams J; Link-Gelles R; Schrag SJ; Verani JR; Ball S; Ong TC
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):139-145. PubMed ID: 35085224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022.
    Modes ME; Directo MP; Melgar M; Johnson LR; Yang H; Chaudhary P; Bartolini S; Kho N; Noble PW; Isonaka S; Chen P
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(6):217-223. PubMed ID: 35143466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-variant protection against SARS-CoV-2 infection in hamsters immunized with monovalent and bivalent inactivated vaccines.
    Ye ZW; Fan Y; Tang K; Ong CP; Luo C; Chung HL; Leong TL; Liang R; Lui WY; Zhou R; Cheng Y; Lu L; Cheung PH; Chan JF; Chen Z; Yuen KY; Yuan S; To KK; Jin DY
    Int J Biol Sci; 2022; 18(12):4781-4791. PubMed ID: 35874942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in population immunity against infection and severe disease from SARS-CoV-2 Omicron variants in the United States between December 2021 and November 2022.
    Klaassen F; Chitwood MH; Cohen T; Pitzer VE; Russi M; Swartwood NA; Salomon JA; Menzies NA
    medRxiv; 2022 Nov; ():. PubMed ID: 36451882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Duration of immune protection of SARS-CoV-2 natural infection against reinfection.
    Chemaitelly H; Nagelkerke N; Ayoub HH; Coyle P; Tang P; Yassine HM; Al-Khatib HA; Smatti MK; Hasan MR; Al-Kanaani Z; Al-Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Butt AA; Al-Romaihi HE; Al-Thani MH; Al-Khal A; Bertollini R; Abu-Raddad LJ
    J Travel Med; 2022 Dec; 29(8):. PubMed ID: 36179099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Reinfection with SARS-CoV-2 Omicron Variants in Previously Infected Hamsters.
    Shiwa-Sudo N; Sakai Y; Iwata-Yoshikawa N; Watanabe S; Yamada S; Kuroda Y; Yamamoto T; Shirakura M; Fujisaki S; Miyazaki K; Miura H; Nagata S; Fukushi S; Maeda K; Hasegawa H; Suzuki T; Nagata N
    J Virol; 2023 Jan; 97(1):e0136622. PubMed ID: 36633406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection Against the Omicron Variant Offered by Previous Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Retrospective Cohort Study.
    Rothberg MB; Kim P; Shrestha NK; Kojima L; Tereshchenko LG
    Clin Infect Dis; 2023 Feb; 76(3):e142-e147. PubMed ID: 35867678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Immunity to Pre-Omicron and Omicron Severe Acute Respiratory Syndrome Coronavirus 2 Variants in US States and Counties Through 1 December 2021.
    Klaassen F; Chitwood MH; Cohen T; Pitzer VE; Russi M; Swartwood NA; Salomon JA; Menzies NA
    Clin Infect Dis; 2023 Feb; 76(3):e350-e359. PubMed ID: 35717642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods - United States, December 2020-January 2022.
    Iuliano AD; Brunkard JM; Boehmer TK; Peterson E; Adjei S; Binder AM; Cobb S; Graff P; Hidalgo P; Panaggio MJ; Rainey JJ; Rao P; Soetebier K; Wacaster S; Ai C; Gupta V; Molinari NM; Ritchey MD
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):146-152. PubMed ID: 35085225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significant Rise in SARS-CoV-2 Reinfection Rate in Vaccinated Hospital Workers during the Omicron Wave: A Prospective Cohort Study.
    Ochoa-Hein E; Leal-Morán PE; Nava-Guzmán KA; Vargas-Fernández AT; Vargas-Fernández JF; Díaz-Rodríguez F; Rayas-Bernal JA; González-González R; Vázquez-González P; Huertas-Jiménez MA; Rajme-López S; Ramos-Cervantes P; Ibarra-González V; García-Andrade LA; Ledesma-Barrientos F; Ponce-de-León A; Sifuentes-Osornio J; Galindo-Fraga A
    Rev Invest Clin; 2022; 74(4):175-180. PubMed ID: 36087938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of mRNA COVID-19 vaccines against Omicron and Delta variants in a matched test-negative case-control study among US veterans.
    Young-Xu Y; Zwain GM; Izurieta HS; Korves C; Powell EI; Smith J; Balajee A; Holodniy M; Beenhouwer DO; Rodriguez-Barradas MC; Brown ST; Marconi VC
    BMJ Open; 2022 Aug; 12(8):e063935. PubMed ID: 35922100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 Vaccine Effectiveness against Omicron Variant among Underage Subjects: The Veneto Region's Experience.
    Cocchio S; Zabeo F; Tremolada G; Facchin G; Venturato G; Marcon T; Saia M; Tonon M; Mongillo M; Da Re F; Russo F; Baldo V
    Vaccines (Basel); 2022 Aug; 10(8):. PubMed ID: 36016248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
    Ferdinands JM; Rao S; Dixon BE; Mitchell PK; DeSilva MB; Irving SA; Lewis N; Natarajan K; Stenehjem E; Grannis SJ; Han J; McEvoy C; Ong TC; Naleway AL; Reese SE; Embi PJ; Dascomb K; Klein NP; Griggs EP; Konatham D; Kharbanda AB; Yang DH; Fadel WF; Grisel N; Goddard K; Patel P; Liao IC; Birch R; Valvi NR; Reynolds S; Arndorfer J; Zerbo O; Dickerson M; Murthy K; Williams J; Bozio CH; Blanton L; Verani JR; Schrag SJ; Dalton AF; Wondimu MH; Link-Gelles R; Azziz-Baumgartner E; Barron MA; Gaglani M; Thompson MG; Fireman B
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(7):255-263. PubMed ID: 35176007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants.
    Chen Y; Chen L; Yin S; Tao Y; Zhu L; Tong X; Mao M; Li M; Wan Y; Ni J; Ji X; Dong X; Li J; Huang R; Shen Y; Shen H; Bao C; Wu C
    Emerg Microbes Infect; 2022 Dec; 11(1):1524-1536. PubMed ID: 35608053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case-case study on the effect of primary and booster immunization with China-produced COVID-19 vaccines on prevention of pneumonia and viral load among vaccinated persons infected by Delta and Omicron variants.
    Wu D; Ye Y; Tang L; Wang AB; Zhang R; Qian ZH; Wang FZ; Zheng H; Huang C; Lv XY; Wang HF; Zhang YY; Pan JJ; Li YF; Lu MX; Wang CS; Ma YT; An ZJ; Rodewald LE; Yin ZD; Wang XY; Wu ZY; Shao YM
    Emerg Microbes Infect; 2022 Dec; 11(1):1950-1958. PubMed ID: 35850623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.